|
|
Vaccine Detail
|
Herpes simplex virus 2 ICP0 mutant vaccine |
| Vaccine Information |
- Vaccine Name: Herpes simplex virus 2 ICP0 mutant vaccine
- Target Pathogen: Herpes simplex virus type 1 and 2
- Target Disease: Herpes
- Vaccine Ontology ID: VO_0002972
- Type: Live, attenuated vaccine
- Status: Research
- Host Species as Laboratory Animal Model: Mouse
- ICP0
gene engineering:
- Type: Gene mutation
- Description: This ICP0 mutant is from Human herpesvirus type 2 (Halford et al., 2011).
- Detailed Gene Information: Click Here.
- Immunization Route: Vaginal immunization
|
| Host Response |
|
Mouse Response
- Persistence: An ICP0 mutant is attenuated in mice (Halford et al., 2011).
- Efficacy: An ICP0 mutant induces protection in mice from challenge with wild type HSV-2 (Halford et al., 2011).
- Host IgG response
- Description: Immunization with the live-attenuated HSV-2 0ΔNLS virus elicited a significant IgG antibody response directed against HSV-2's entry receptor, gD-2. gD-2 specific IgG antibodies were detected at levels significantly higher than levels detected in naive mice at day 50 after inoculation (Halford et al., 2011).
- Detailed Gene Information: Click Here.
|
| References |
Halford et al., 2011: Halford WP, Püschel R, Gershburg E, Wilber A, Gershburg S, Rakowski B. A live-attenuated HSV-2 ICP0 virus elicits 10 to 100 times greater protection against genital herpes than a glycoprotein D subunit vaccine. PloS one. 2011; 6(3); e17748. [PubMed: 21412438].
|
|
